YCBD

SEC source: 0001437749-22-020197 · rdgdoc.xml · nonDerivative · entry 1

Swift Sibyl Nichole · CIK 0001942359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,250

F1 · security: The restricted shares of common stock were issued under the 2015 Equity Compensation Plan as compensation to the Reporting Person for her services on the Issuer's Board of Directors for the Board term beginning August 9, 2022. The issuance was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The shares vested upon issuance.

SEC source: 0001654954-22-011089 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 16,860,746

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On August 9, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 409,505 shares of its common stock representing the June 30, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 268,840 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On August 9, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 409,505 shares of its common stock representing the June 30, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 268,840 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 13,176,746 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 11,471,812 shares of common stock held by the Coffman Family Office. The balance of 1,436,094 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 1,436,094 shares vest on December 20, 2023.

SEC source: 0001654954-22-007214 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 1,894,533

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 41,299 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 41,299 Earnout Shares to the Family Trust.

F2 · ownership.nature: Includes 250,000 shares of common stock held directly by the Reporting Person and 1,644,553 shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,250,803 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-22-007215 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 16,591,906

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 301,253 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On May 17, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2022 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 458,877 shares of its common stock representing the March 31, 2022 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 301,253 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 12,907,906 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 10,035,718 shares of common stock held by the Coffman Family Office. The balance of 2,872,188 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 2,872,188 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-22-007147 · section16.xml · derivative · entry 2

MacDermott Kevin · CIK 0001928755 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,000

Underlying: Common Stock · 405,000 shares

Expires 2022-05-16

F2 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025.

F2 · price: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025.

F2 · derivative.exercise_date: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person as the Issuer's President beginning May 16, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The options vest annually in three equal increments on May 15, 2023, May 15, 2024, and May 15, 2025.

SEC source: 0001654954-22-007147 · section16.xml · nonDerivative · entry 1

MacDermott Kevin · CIK 0001928755 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,000

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022.

F1 · price: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units were issued under the 2021 Equity Compensation Plan as partial compensation to the Reporting Person for his services as the Issuer's President beginning May 16, 2022.

SEC source: 0001654954-22-005072 · section16.xml · derivative · entry 2

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-03-11

F2 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.

F3 · price: Not applicable.

SEC source: 0001654954-22-005072 · section16.xml · nonDerivative · entry 1

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,531

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.

SEC source: 0001654954-22-005149 · section16.xml · derivative · entry 2

Stephen Scott G. · CIK 0001773957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-03-11

F2 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.

F3 · price: Not applicable.

SEC source: 0001654954-22-005149 · section16.xml · nonDerivative · entry 1

Stephen Scott G. · CIK 0001773957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,052

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.

SEC source: 0001654954-22-005147 · section16.xml · derivative · entry 3

Raines William F III · CIK 0001773698 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-03-11

F3 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.

F4 · price: Not applicable.

SEC source: 0001654954-22-005147 · section16.xml · nonDerivative · entry 1

Raines William F III · CIK 0001773698 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,342

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.

SEC source: 0001654954-22-005145 · section16.xml · derivative · entry 2

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-03-11

F2 · security: The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.

F3 · price: Not applicable.

SEC source: 0001654954-22-005145 · section16.xml · nonDerivative · entry 1

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,000

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.

SEC source: 0001654954-22-002405 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 2

Disclosed balance after: 1,853,254

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On February __, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 39,982 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On February __, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 39,982 Earnout Shares to the Family Trust.

F2 · ownership.nature: Includes 250,000 shares of common stock held directly by the Reporting Person and 1,603,254 shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,209,504 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-22-002406 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · CO-CEO, President, Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote 2

Disclosed balance after: 16,290,653

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On February 28, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 291,646 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On February 28, 2022 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the December 31, 2021 quarter of the Third Marketing Period had been achieved and the Issuer issued an aggregate of 444,243 shares of its common stock representing the December 31, 2021 Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 291,646 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 12,606,653 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 9,734,465 shares of common stock held by the Coffman Family Office. The balance of 2,872,188 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 2,872,188 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-22-000045 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on April 19, 2021 and vested on January 1, 2022.

F4 · derivative.expiration_date: The restricted stock units were granted on April 19, 2021 and vested on January 1, 2022.

SEC source: 0001654954-22-000045 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares of common stock issued upon vesting of restricted stock units on January 1, 2022.

SEC source: 0001654954-21-013625 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,563,272

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 42,004 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 42,004 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,169,522 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-013624 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · CO-CEO, President, Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,999,007

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter of the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 306,397 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On December 28, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the September 30, 2021 quarter of the Third Marking Period had been achieved and the Issuer issued an aggregate of 466,713 shares of its common stock representing the September 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 306,397 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 12,315,007 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 9,442,819 shares of common stock held by the Coffman Family Office. The balance of 2,872,188 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 2,872,188 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-21-010812 · section16.xml · derivative · entry 4

Kennedy Thomas Ronan · CIK 0001826452 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2026-10-01

F5 · security: The stock options were granted under the 2015 Equity Compensation Plan pursuant to the terms of the Executive Employment Agreement dated October 1, 2021, by and between the Issuer and the Reporting Person. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The stock options vest on October 1, 2022, subject to continued employment on the applicable vesting date.

F6 · price: Not applicable.

SEC source: 0001654954-21-010812 · section16.xml · derivative · entry 3

Kennedy Thomas Ronan · CIK 0001826452 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on October 1, 2021 and vest on October 1, 2022.

F4 · derivative.expiration_date: The restricted stock units were granted on October 1, 2021 and vest on October 1, 2022.

SEC source: 0001654954-21-010812 · section16.xml · nonDerivative · entry 2

Kennedy Thomas Ronan · CIK 0001826452 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,067

F2 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted stock units shall vest on January 1, 2022. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2015 Equity Compensation Plan pursuant to the terms of the Executive Employment Agreement dated October 1, 2021, by and between the Issuer and the Reporting Person.

SEC source: 0001654954-21-010812 · section16.xml · nonDerivative · entry 1

Kennedy Thomas Ronan · CIK 0001826452 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,067

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares of common stock to be issued upon the vesting of restricted stock units which vest on October 1, 2021.

SEC source: 0001654954-21-010548 · section16.xml · nonDerivative · entry 2

Wiesehan John J III · CIK 0001875037 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,450

F1 · kind: The common stock was issued as partial consideration pursuant to that certain Asset Purchase Agreement dated July 22, 2021, by and among Twenty Two Capital, LLC ("Twenty Two"), the Issuer, the Reporting Person, and the other parties named therein, with 300,000 shares of common stock issued at closing of the Asset Purchase Agreement. On September 28, 2021, Twenty Two transferred a limited number of shares and distributed the remaining shares to its members on a pro rata basis. Represents the distribution of the shares by Twenty Two and the acquisition of the pro rata number of shares distributed to the Reporting Person, a member of Twenty Two as approved by the Issuer's board of directors and exempt under Section 16b-3.

F1 · price: The common stock was issued as partial consideration pursuant to that certain Asset Purchase Agreement dated July 22, 2021, by and among Twenty Two Capital, LLC ("Twenty Two"), the Issuer, the Reporting Person, and the other parties named therein, with 300,000 shares of common stock issued at closing of the Asset Purchase Agreement. On September 28, 2021, Twenty Two transferred a limited number of shares and distributed the remaining shares to its members on a pro rata basis. Represents the distribution of the shares by Twenty Two and the acquisition of the pro rata number of shares distributed to the Reporting Person, a member of Twenty Two as approved by the Issuer's board of directors and exempt under Section 16b-3.

SEC source: 0001654954-21-010548 · section16.xml · nonDerivative · entry 1

Wiesehan John J III · CIK 0001875037 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Twenty Two Capital LLC

Disclosed balance after: 0

F1 · kind: The common stock was issued as partial consideration pursuant to that certain Asset Purchase Agreement dated July 22, 2021, by and among Twenty Two Capital, LLC ("Twenty Two"), the Issuer, the Reporting Person, and the other parties named therein, with 300,000 shares of common stock issued at closing of the Asset Purchase Agreement. On September 28, 2021, Twenty Two transferred a limited number of shares and distributed the remaining shares to its members on a pro rata basis. Represents the distribution of the shares by Twenty Two and the acquisition of the pro rata number of shares distributed to the Reporting Person, a member of Twenty Two as approved by the Issuer's board of directors and exempt under Section 16b-3.

F1 · price: The common stock was issued as partial consideration pursuant to that certain Asset Purchase Agreement dated July 22, 2021, by and among Twenty Two Capital, LLC ("Twenty Two"), the Issuer, the Reporting Person, and the other parties named therein, with 300,000 shares of common stock issued at closing of the Asset Purchase Agreement. On September 28, 2021, Twenty Two transferred a limited number of shares and distributed the remaining shares to its members on a pro rata basis. Represents the distribution of the shares by Twenty Two and the acquisition of the pro rata number of shares distributed to the Reporting Person, a member of Twenty Two as approved by the Issuer's board of directors and exempt under Section 16b-3.

F2 · ownership.nature: Represents the Reporting Person's pecuniary interest in the 300,000 shares of the Issuer acquired by Twenty Two pursuant to the APA. The Reporting Person is the holder of a 53.85% membership interest in Twenty Two and a manager of Twenty Two.

SEC source: 0001654954-21-009413 · section16.xml · derivative · entry 2

Kennedy Thomas Ronan · CIK 0001826452 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,300

Underlying: Common Stock · 3,834 shares

Expires not disclosed

F1 · derivative.exercise_date: The Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") has no stated maturity and will remain outstanding indefinitely unless a holder chooses to convert the Preferred Stock into shares of the Issuer's common stock at any time, the Issuer elects to automatically convert it into shares of its common stock upon a "Market Trigger", as defined in the Issuer's Certificate of Designations, Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock filed on October 11, 2019 (the "Designation"), on or after October 16, 2023 the Issuer elects to redeem it, or a Change of Control, (as defined in the Designation) occurs resulting in a mandatory redemption. The Issuer may elect to automatically convert some or all of the Preferred Stock into shares of its common stock if the closing price of the common stock has exceeded $8.25 (137.5% of the Conversion Price) for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. The Preferred Stock will not be redeemable before October 16, 2023 except as described below upon the occurrence of a Change of Control. Commencing on October 16, 2023, the Issuer may redeem, at its option, the Preferred Stock, in whole or in part, at a cash redemption price of $10.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. Upon the occurrence of a Change of Control the Issuer is required to redeem any or all of the shares of Series A Convertible Preferred Stock at a redemption price of $11.00 per share, plus any accrued but unpaid dividends to, but excluding, the redemption date.

F1 · derivative.expiration_date: The Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") has no stated maturity and will remain outstanding indefinitely unless a holder chooses to convert the Preferred Stock into shares of the Issuer's common stock at any time, the Issuer elects to automatically convert it into shares of its common stock upon a "Market Trigger", as defined in the Issuer's Certificate of Designations, Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock filed on October 11, 2019 (the "Designation"), on or after October 16, 2023 the Issuer elects to redeem it, or a Change of Control, (as defined in the Designation) occurs resulting in a mandatory redemption. The Issuer may elect to automatically convert some or all of the Preferred Stock into shares of its common stock if the closing price of the common stock has exceeded $8.25 (137.5% of the Conversion Price) for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. The Preferred Stock will not be redeemable before October 16, 2023 except as described below upon the occurrence of a Change of Control. Commencing on October 16, 2023, the Issuer may redeem, at its option, the Preferred Stock, in whole or in part, at a cash redemption price of $10.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. Upon the occurrence of a Change of Control the Issuer is required to redeem any or all of the shares of Series A Convertible Preferred Stock at a redemption price of $11.00 per share, plus any accrued but unpaid dividends to, but excluding, the redemption date.

SEC source: 0001654954-21-009413 · section16.xml · nonDerivative · entry 1

Kennedy Thomas Ronan · CIK 0001826452 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

SEC source: 0001654954-21-009280 · section16.xml · derivative · entry 1

Wiesehan John J III · CIK 0001875037 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 3,334 shares

Expires not disclosed

F1 · derivative.exercise_date: The Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") has no stated maturity and will remain outstanding indefinitely unless a holder chooses to convert the Preferred Stock into shares of the Issuer's common stock at any time, the Issuer elects to automatically convert it into shares of its common stock upon a "Market Trigger", as defined in the Issuer's Certificate of Designations, Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock filed on October 11, 2019 (the "Designation"), on or after October 16, 2023 the Issuer elects to redeem it, or a Change of Control, (as defined in the Designation) occurs resulting in a mandatory redemption. The Issuer may elect to automatically convert some or all of the Preferred Stock into shares of its common stock if the closing price of the common stock has exceeded $8.25 (137.5% of the Conversion Price) for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. The Preferred Stock will not be redeemable before October 16, 2023 except as described below upon the occurrence of a Change of Control. Commencing on October 16, 2023, the Issuer may redeem, at its option, the Preferred Stock, in whole or in part, at a cash redemption price of $10.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. Upon the occurrence of a Change of Control the Issuer is required to redeem any or all of the shares of Series A Convertible Preferred Stock at a redemption price of $11.00 per share, plus any accrued but unpaid dividends to, but excluding, the redemption date.

F1 · derivative.expiration_date: The Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") has no stated maturity and will remain outstanding indefinitely unless a holder chooses to convert the Preferred Stock into shares of the Issuer's common stock at any time, the Issuer elects to automatically convert it into shares of its common stock upon a "Market Trigger", as defined in the Issuer's Certificate of Designations, Rights and Preferences of the 8% Series A Cumulative Convertible Preferred Stock filed on October 11, 2019 (the "Designation"), on or after October 16, 2023 the Issuer elects to redeem it, or a Change of Control, (as defined in the Designation) occurs resulting in a mandatory redemption. The Issuer may elect to automatically convert some or all of the Preferred Stock into shares of its common stock if the closing price of the common stock has exceeded $8.25 (137.5% of the Conversion Price) for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. The Preferred Stock will not be redeemable before October 16, 2023 except as described below upon the occurrence of a Change of Control. Commencing on October 16, 2023, the Issuer may redeem, at its option, the Preferred Stock, in whole or in part, at a cash redemption price of $10.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. Upon the occurrence of a Change of Control the Issuer is required to redeem any or all of the shares of Series A Convertible Preferred Stock at a redemption price of $11.00 per share, plus any accrued but unpaid dividends to, but excluding, the redemption date.

SEC source: 0001654954-21-009235 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,521,244

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 45,295 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the Third Marking Period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter within the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement. Included in this issuance was the issuance of 45,295 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,127,494 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-009233 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · CO-CEO, President, Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 15,690,432

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter of the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 330,400 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months (the "Third Marking Period"), and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the Third Marking Period to change the determination of the aggregate net revenues within the Third Marking Period to a quarterly basis for each of the six fiscal quarters within the Third Marking Period, beginning with the quarter ended March 31, 2021, instead of following the Third Marking Period end date which was 18 months after the beginning of the third marking period. On August 16, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the June 30, 2021 quarter of the Third Marking Period had been achieved and the Issuer issued an aggregate of 503,275 shares of its common stock representing the June 30, 2021 quarter of the Third Marking Period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 330,400 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 12,006,432 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 8,765,108 shares of common stock held by the Coffman Family Office. The balance of 2,872,188 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 2,872,188 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-21-008222 · section16.xml · nonDerivative · entry 1

Wiesehan John J III · CIK 0001875037 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Twenty Two Capital LLC

Disclosed balance after: 161,550

F1 · price: The common stock was issued as partial consideration pursuant to that certain Asset Purchase Agreement, dated July 22, 2021, by and among Twenty Two Capital, LLC ("Twenty Two"), the Issuer, the Reporting Person, and the other parties named therein (the "APA"). Pursuant to the APA, the Issuer agreed to acquire certain assets, including among others, tangible personal property, inventories, accounts receivable, contracts, governmental authorizations, intangible rights and property, and insurance benefits, subject to certain exclusions, in exchange for (i) $2,000,000 in cash, subject to adjustment per the APA, (ii) 600,000 shares of the Issuer's common stock, with (x) 300,000 shares issued at closing, (y) 100,000 shares to be issued on or before January 31, 2023, subject to certain set-off obligations, and (z) the remainder to be issued on or before the 60th day following the first year anniversary of the closing, subject to certain adjustments, and assume certain liabilities as provided for in the APA.

F2 · ownership.nature: Represents the Reporting Person's pecuniary interest in the 300,000 shares of the Issuer acquired by Twenty Two pursuant to the APA. The Reporting Person is the holder of a 53.85% membership interest in Twenty Two and has shared voting and investment power over its portfolio securities.

SEC source: 0001654954-21-006009 · section16.xml · nonDerivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,475,949

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter within the third marking period had been achieved and the Issuer issued an aggregate of 572,278 shares of its common stock representing the March 31, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 50,605 Earnout Shares to the Family Trust.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including the Sumichrast 2017 Family Trust ("Family Trust"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter within the third marking period had been achieved and the Issuer issued an aggregate of 572,278 shares of its common stock representing the March 31, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 50,605 Earnout Shares to the Family Trust.

F2 · ownership.nature: Represents shares of common stock that are held of record by the Family Trust. The Reporting Person has the sole power to dispose of the shares of common stock held of record by the Family Trust. The Reporting Person has the sole right to vote 1,082,199 shares of common stock held by the Family Trust and the balance of 393,750 shares are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Family Trust pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 393,750 shares vest in equal portions on each of June 20, 2022 and December 20, 2023. The Reporting Person disclaims beneficial ownership of the securities held of record by the Family Trust except to the extent of his pecuniary interest therein.

SEC source: 0001654954-21-006007 · section16.xml · nonDerivative · entry 1

Coffman Raymond Scott · CIK 0001761772 · Director · CO-CEO, President, Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,360,032

F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter of the third marking period had been achieved and the Issuer issued an aggregate of 562,278 shares of its common stock representing the March 1, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 369,136 Earnout Shares to Coffman Family Office.

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated December 3, 2018 by and between the Issuer, its wholly owned subsidiaries, and Cure Based Development, LLC which closed on December 20, 2018 (the "Closing Date"), CBD Holding, LLC ("CBDH"), then the sole member of Cure Based Development, LLC, was entitled to receive (the "Earnout Rights") up to 15,250,000 additional shares of the Issuer's common stock for no additional consideration (the "Earnout Shares") as part of the merger consideration, which such Earnout Shares were to be issued upon the satisfaction of certain aggregate net revenue criteria within 60 months following the Closing Date, as measured at four intervals from the Closing Date of 12 calendar months, 24 calendar months, 42 calendar months, and 59 calendar months. The issuance of the Earnout Shares was approved by the Issuer's shareholders in April 2019. On February 26, 2020 in connection with its dissolution and liquidation and pursuant to the terms of a Distribution Agreement, CBDH distributed the Earnout Rights to its members, including Coffman Family Office, LLC ("Coffman Family Office"), on a pro rata basis. On March 31, 2021 the Issuer entered into Addendum No. 1 to the Merger Agreement with the members of CBDH which amended the measurement periods within the third marking period to change the determination of the aggregate net revenues within the third marking period to a quarterly basis for each of the six fiscal quarters within the third marking period, beginning with the quarter ended March 31, 2021, instead of following third marking period end date which was 18 months after the beginning of the third marking period. On May 14, 2021 in accordance with the terms of the Merger Agreement, as amended, the Issuer determined that the net revenue criteria for the March 31, 2021 quarter of the third marking period had been achieved and the Issuer issued an aggregate of 562,278 shares of its common stock representing the March 1, 2021 quarter of the third marking period Earnout Shares which were earned under the terms of the Merger Agreement, as amended. Included in this issuance was the issuance of 369,136 Earnout Shares to Coffman Family Office.

F2 · ownership.nature: Includes (i) 3,684,000 shares held of record by Edge of Business, LLC ("Edge of Business"); and (ii) 11,676,032 shares held of record by the Coffman Family Office. The Reporting Person disclaims beneficial ownership of the securities held of record by each of these entities except to the extent of his pecuniary interest therein. The Reporting Person has the sole power to vote and dispose of all of the shares of common stock held of record by Edge of Business. Coffman Management, LLC ("Coffman Management") is the Manager of the Coffman Family Office and the Reporting Person is the Manager of Coffman Management. The Reporting Person has sole power to dispose of all shares of common stock held by the Coffman Family Office and sole right to vote 8,803,855 shares of common stock held by the Coffman Family Office. The balance of 2,872,188 shares of common stock held of record by the Coffman Family Office are subject to the terms of a Voting Trust Agreement dated February 26, 2020 between the Issuer and the Coffman Family Office pursuant to which until such time as the unrestricted voting rights to these shares have vested, the voting rights to such shares are held by the independent chairman of the Audit Committee of the Issuer's board of directors who will vote such shares on any matter brought before the Issuer's shareholders in accordance with the recommendation of its board of directors. The voting rights to the 2,872,188 shares vest in equal portions on each of June 20, 2022 and December 20, 2023.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 6

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2024-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 5

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2023-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 4

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2022-01-01

F2 · security: Represents grants of restricted stock awards to the Reporting Person under the 2021 Plan pursuant to the terms and conditions of the Sumichrast Employment Agreement.

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 3

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2029-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 2

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2028-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-004492 · section16.xml · derivative · entry 1

Sumichrast Martin A. · CIK 0001427722 · Director · Chairman & CO-CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common stock · 250,000 shares

Expires 2027-01-01

F1 · security: Represents grants of stock options to the Reporting Person under the Issuer's 2021 Equity Compensation Plan (the "2021 Plan") pursuant to the terms and conditions of the Amended and Restated Executive Employment Agreement dated April 19, 2012 by and between the Issuer and the Reporting Person (the "Sumichrast Employment Agreement").

SEC source: 0001654954-21-002825 · section16.xml · derivative · entry 5

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-03-11

SEC source: 0001654954-21-002825 · section16.xml · derivative · entry 4

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2022-03-12

SEC source: 0001654954-21-002825 · section16.xml · derivative · entry 3

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-12-31

SEC source: 0001654954-21-002825 · section16.xml · derivative · entry 2

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-09-30

SEC source: 0001654954-21-002825 · section16.xml · derivative · entry 1

Ghiloni Peter J. · CIK 0001773696 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-06-30

SEC source: 0001654954-21-002824 · section16.xml · derivative · entry 5

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-03-11

SEC source: 0001654954-21-002824 · section16.xml · derivative · entry 4

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2022-03-12

SEC source: 0001654954-21-002824 · section16.xml · derivative · entry 3

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-12-31

SEC source: 0001654954-21-002824 · section16.xml · derivative · entry 2

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-09-30

SEC source: 0001654954-21-002824 · section16.xml · derivative · entry 1

Sellers Bakari T. · CIK 0001721556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2021-06-30